Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat

About this update from Acurx Pharmaceuticals, Inc.

STATEN ISLAND, N.Y., Aug. 17, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proposed proprietary, or brand name, CIFBEZY for ibezapolstat, the Company's lead antibiotic product candidate being developed for both the acute treatment and the reduction of recurrence of CDI. The Company also announced that the U.S. Patent and Trademark Office (USPTO) has allowed the trademark application for CIFBEZY. These independently-determined initial milestones to establish the proprietary name for ibezapolstat consider both regulatory and intellectual-property aspects. For the regulatory aspect, commercial use is contingent upon approval of a US NDA (New Drug Approval) and is focused on patient safety and the prevention of medication errors. For the intellectual property aspect, the notice of allowance shows that the trademark has passed through both the examination process and the opposition period. Securing both a registration and proprietary name will provide Acurx with a protected brand name as it advances ibezapolstat into international Phase 3 clinical trials toward an NDA approval and ultimate commercialization. The proprietary name CIFBEZY (pronounced "sif-BEZ-ee") was developed through an extensive screening process involving external branding experts, prescribers, pharmacists and linguists, as required and evaluated by FDA's Division of Medication Error Prevention and Analysis (DMEPA) consistent with the FDA's Guidance for Industry: Contents of a Complete Submission for the Evaluation of Proprietary Names. "Receiving both FDA conditional acceptance and USPTO trademark allowance for CIFBEZY are meaningful milestones as a placeholder that move ibezapolstat one step closer to preparation for commercialization" said Robert J. DeLuccia, Acurx's Executive Chairman: "With ibezapolstat preparing to advance into its international Phase 3 registration program for treatment of both CDI and reduction of recurrence and the initiation of a ground-breaking clinical trial in patients with multiply-recurrent CDI (rCDI), we believe ibezapolstat has the potential to be the first anti-CDI antibiotic to demonstr...

View stock analysis, news, and events for Acurx Pharmaceuticals, Inc.